Revvity Inc. (RVTY)
NYSE: RVTYIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
At close: Oct 7, 4:02 PM ET · Delayed 15 min
After hours: 153.60 0.00%
RVTY stock chart
Technical analysisKey statistics
All statistics- Market cap
- $17.14B
- P/E (TTM)
- 73.49
- Forward P/E
- 26.07
- EPS (TTM)
- $2.09
- Dividend yield
- 0.18% ($0.28)
- Ex-dividend date
- Jul 17, 2026
- 52-week range
- 81.22 – 166.25
- Day range
- 149.36 – 156.00
- Volume / Avg
- 2.23M / 1.77M
- Beta
- —
- Shares outstanding
- 111.59M
- Next earnings
- Nov 3, 2026
52-week range
RVTY stock today
On Oct 7, RVTY ended the session at $153.60, adding $0.30 (0.20%), versus the S&P 500's 0.22% decline. Shares are 7.6% below their 52-week high of $166.25, set on Oct 6, 2026 and 89.1% above the 52-week low of $81.22, near the top of the past year's range. RVTY is up 59.2% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 68.9%.
Revvity trades at 73.5x its trailing twelve-month earnings per share of $2.09. Its forward P/E of 26.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Revvity's next earnings report is expected on Nov 3, 2026. Revvity pays an annual dividend of $0.28 per share, a 0.18% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Revvity
Company profileRevvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- CEO
- Dr. Prahlad R. Singh Ph.D.
- Headquarters
- Waltham, MA
- Employees
- 11,000
- Website
- revvity.com
Financial highlights
Full financialsIn fiscal 2025, Revvity generated $2.86 billion in revenue, up 3.7% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $241.2 million (-10.8% year over year), for a net margin of 8.4% versus a median of 19.2% in the prior 5 years. Operating margin was 12.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $2.86B | $2.76B | $2.75B | $3.31B | $3.83B |
| Growth | +3.67% | +0.16% | -16.95% | -13.48% | +1.19% |
| Net income | $241.20M | $270.38M | $693.09M | $569.18M | $943.16M |
| EPS (diluted) | $2.07 | $2.20 | $5.55 | $4.50 | $8.08 |
Analyst forecast
ForecastConsensus (18 analysts)
buy
Avg. price target
$135.87-11.54%
- Strong buy 0
- Buy 6
- Hold 11
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 3, 2026
- EPS estimate
- $1.28
- Last reported (Q2 2026)
- Aug 11, 2026
- EPS actual vs est.
- $0.47 vs —
Dividends
Dividend history- Annual dividend
- $0.28
- Dividend yield
- 0.18%
- Last payment
- $0.07
- Ex-dividend date
- Jul 17, 2026
RVTY news
All RVTY newsRevvity peers
Industrials sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AVTRAvantor Inc. | 15.35 | -0.52% | $10.38B | vs RVTY |
| TXG10x Genomics Inc. Class A | 76.10 | -5.65% | $9.92B | vs RVTY |
| BIOBio-Rad Laboratories Inc. Class A | 367.92 | -0.25% | $9.84B | vs RVTY |
| BRKRBruker Corporation | 59.72 | -1.29% | $9.10B | vs RVTY |
| MTDMettler-Toledo International Inc. | 1,533.48 | +0.03% | $30.73B | vs RVTY |
| ALMRAlamar Biosciences Inc. | 27.77 | -13.92% | $1.93B | vs RVTY |
| PACBPacific Biosciences of California Inc. | 2.72 | +0.74% | $845.46M | vs RVTY |
| CTKBCytek Biosciences Inc. | 5.34 | -0.74% | $694.11M | vs RVTY |
Indexes, lists and sector
Index membership
Appears in lists
Revvity stock FAQ
What is Revvity's stock price today?
RVTY last traded at $153.60 as of Oct 7, 4:02 PM EDT, up 0.20% on the day. Prices are delayed at least 15 minutes.
Does Revvity pay a dividend?
Yes. Revvity pays $0.28 per share annually, a 0.18% yield. The most recent dividend of $0.07 had an ex-dividend date of Jul 17, 2026.
When is Revvity's next earnings date?
Revvity is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $1.28.
What is RVTY's P/E ratio?
RVTY trades at a trailing P/E ratio of 73.49 and a forward P/E of 26.07.
Is Revvity in the S&P 500?
Yes. Revvity (RVTY) is a constituent of the S&P 500 index.
Who is Revvity's CEO?
Dr. Prahlad R. Singh Ph.D. is the chief executive officer of Revvity Inc., which has about 11,000 employees.
Has RVTY ever split its stock?
Yes. The most recent RVTY stock split was a 2-for-1 split on Jun 4, 2001, one of 4 splits on record.